Replies to post #144273 on NanoViricides Inc. (NNVC)

[KMBJN]

I don't get it. Is the criticism here that Diwan isn't doing enough or he is doing too much with his efforts against SARS2?

I think he did just enough to raise some funds needed for ShinglesCide, so well-played. He set the company in a position to benefit from all the focus on SARS2, but so far the only benefit to NNVC is raising more funds with less dilution with the renewed attention they've gotten. (Remember all those posts about how NNVC would have been bankrupt like 2 or 3 years ago? Same drivel over and over and over again?) There is also the possible benefit that some third party (government or drug company partner) will give more funds to help develop CoVCide. Anything which gives more confidence to the platform will be helpful for shareholders.

In the mean time, while they wait on someone to run actual SARS2 in vitro studies, or government funds, or a partner to advance further, they really need to focus on topical ShinglesCide, to get that first IND and first trial planned, to prove to investors that they are a serious biotech company with actual products that will be tested in humans.